Correlación entre la expresión de Ki67 con factores clásicos pronósticos y predictivos en el cáncer de mama precoz

Cusati, Mariana Panal; Muela, María Herrera de la; Hernáez, David Hardisson; Dionisio, M.; Guindo, A; García, F.J.

doi:10.1016/j.senol.2014.07.005

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Generally, luminal tumors exhibit low Ki-67 levels. In research conducted by Viale et al, the prognostic and predictive value of Ki-67 was explored, revealing that higher values correlate with a poorer prognosis [30].…”

Section: Histological Biomarkersmentioning

confidence: 99%

Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice

Lopez-Gonzalez,

Sanchez Cendra,

Sanchez Cendra

et al. 2024

Medicina

View full text Add to dashboard Cite

Breast cancer is a prevalent malignancy in the present day, particularly affecting women as one of the most common forms of cancer. A significant portion of patients initially present with localized disease, for which curative treatments are pursued. Conversely, another substantial segment is diagnosed with metastatic disease, which has a worse prognosis. Recent years have witnessed a profound transformation in the prognosis for this latter group, primarily due to the discovery of various biomarkers and the emergence of targeted therapies. These biomarkers, encompassing serological, histological, and genetic indicators, have demonstrated their value across multiple aspects of breast cancer management. They play crucial roles in initial diagnosis, aiding in the detection of relapses during follow-up, guiding the application of targeted treatments, and offering valuable insights for prognostic stratification, especially for highly aggressive tumor types. Molecular markers have now become the keystone of metastatic breast cancer diagnosis, given the diverse array of chemotherapy options and treatment modalities available. These markers signify a transformative shift in the arsenal of therapeutic options against breast cancer. Their diagnostic precision enables the categorization of tumors with elevated risks of recurrence, increased aggressiveness, and heightened mortality. Furthermore, the existence of therapies tailored to target specific molecular anomalies triggers a cascade of changes in tumor behavior. Therefore, the primary objective of this article is to offer a comprehensive review of the clinical, diagnostic, prognostic, and therapeutic utility of the principal biomarkers currently in use, as well as of their clinical impact on metastatic breast cancer. In doing so, our goal is to contribute to a more profound comprehension of this complex disease and, ultimately, to enhance patient outcomes through more precise and effective treatment strategies.

show abstract

Section: Histological Biomarkersmentioning

confidence: 99%

Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice

Lopez-Gonzalez,

Sanchez Cendra,

Sanchez Cendra

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…En cuanto al cáncer de mama tipo normal, es similar a la enfermedad luminal A. Es ER y/o PR positivo, HER2 negativo, y tiene bajos niveles de la proteı ńa Ki-67, un antı ǵeno nuclear presente en los estadı ós tempranos del cáncer de mama relacionado con la proliferación celular y asociado con un mal diagnóstico, pero con buena respuesta a la quimioterapia [40].…”

Section: Los Carcinomas Surgen Del Componente Epitelial Deunclassified

Cáncer de mama triple negativo: generalidades, situación en Costa Rica y nuevas tendencias para su tratamiento.

Meza¹,

Arias²,

Quesada³

et al. 2018

Rev Med UCR

View full text Add to dashboard Cite

El cáncer de mama es una proliferación clonal de células neoplásicas que inicia en la mama. El mismo se categoriza de acuerdo al subtipo histológico, al tamaño tumoral y al estadío. El subtipo histológico más agresivo es el triple negativo, siendo negativo para los receptores de estrógenos, progesterona y crecimiento epidérmico humano. A lo largo de la historia, el tratamiento contra este cáncer ha cambiado. Actualmente, el mismo consiste en una combinación de radioterapia, quimioterapia y cirugía. Sin embargo, se están investigando nuevas estrategias terapéuticas basadas en la inmunoterapia, las cuales han brindado resultados prometedores en estudios clínicos. La integración de inmunoterapias activas y pasivas como las vacunas y los anticuerpos monoclonales, y el uso de inhibidores de poli (adenosín difosfato o ADP-ribosa) polimerasa, solos o en conjunto con terapias clásicas, son alternativas para incrementar las posibilidades farmacoterapéuticas contra este tipo de cáncer.

show abstract

Validation of prognostic and predictive value of total tumoral load after primary systemic therapy in breast cancer using OSNA assay

Bernet-Vegué,

Cantero-González,

Sancho de Salas

et al. 2023

Clin Transl Oncol

View full text Add to dashboard Cite

Purpose This study aimed to validate the classification of breast cancer (BC) patients in progression risk groups based on total tumor load (TTL) value to predict lymph node (LN) affectation after neo-adjuvant systemic therapy (NAST) obtained in the NEOVATTL study. Methods/patients This was an observational, retrospective, international, multicenter study including patients with infiltrating BC who received NAST followed by sentinel lymph node biopsy (SLNB) analyzed with one-step nucleic acid amplification (OSNA) from nine Spanish and two Italian hospitals. Patients were classified into three groups according to the progression risk, measured as disease-free survival (DFS), based on TTL values (> 250, 250–25,000, and > 25,000 copies/μL). The previous (NEOVATTL study) Cox regression model for prognosis was validated using prognostic index (PI) and Log ratio test (LRT) analyses; the value of TTL for axillary non-SLN affectation was assessed using receiver operating characteristic (ROC) curves. Results We included 263 patients with a mean age of 51.4 (± SD 10.5) years. Patients with TTL > 25,000 copies/μL had a shorter DFS (HR 3.561 [95% CI 1.693−7.489], p = 0.0008 vs. TTL ≤ 25,000). PI and LRT analyses showed no differences between the two cohorts (p = 0.2553 and p = 0.226, respectively). ROC analysis showed concordance between TTL and non-SLN involvement (area under the curve 0.828), with 95.7% sensitivity and 92.9% specificity at a TTL cut-off of > 15,000 copies/μL. Conclusions In BC patients who had received NAST and underwent SLNB analysis using OSNA, a TTL value of > 25,000 copies/μL was associated with a higher progression risk and > 15,000 copies/μL was predictive of non-SLN involvement.

show abstract

Correlación entre la expresión de Ki67 con factores clásicos pronósticos y predictivos en el cáncer de mama precoz

Cited by 5 publications

References 26 publications

Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice

Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice

Cáncer de mama triple negativo: generalidades, situación en Costa Rica y nuevas tendencias para su tratamiento.

Validation of prognostic and predictive value of total tumoral load after primary systemic therapy in breast cancer using OSNA assay

Contact Info

Product

Resources

About